Archive for News Report

Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally

February 11, 2026

Mediar gains $76M for clinical trials of three fibrosis drugs

January 7, 2026

Boehringer spells out a $448M future for Rectify’s ABC kidney disease program

December 23, 2025

Reinventing Drug Discovery with AI: Marc Tessier-Lavigne on The Long Run

November 14, 2025

Inflammation biotech Evommune heads to NYSE with $150M IPO

November 10, 2025

Evommune nabs $150M in IPO amid federal shutdown

November 10, 2025